stockrowTrulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
Follow TRLV
Alert me
Trulieve Cannabis Corp. (TRLV) Current ratio
Trulieve Cannabis Corp.'s current ratio at the end of the quarter to 30 September 2026 was 5.5×, up 1.1× from fiscal 2025 (4.4×). Over the past ten years it has ranged from 2.8× (fiscal 2022) to 4.4× (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of 2.4× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 4.4× | 1.54% |
| FY2024 | 4.4× | 5.03% |
| FY2023 | 4.2× | 47.26% |
| FY2022 | 2.8× | (8.89%) |
| FY2021 | 3.1× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 5.5× | (7.11%) |
| Jun 2026 | 5.9× | 12.99% |
| Mar 2026 | 5.3× | 18.64% |
| Dec 2025 | 4.4× | (27.26%) |
| 16 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| RGC Regencell Bioscience Holdings Limited compare | 10.8× |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 5.6× |
| TRLV Trulieve Cannabis Corp. | 5.5× |
| PBH Prestige Consumer Healthcare Inc. compare | 2.9× |
| ANIP ANI Pharmaceuticals, Inc. compare | 2.7× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 2.7× |
| PRGO Perrigo Company plc compare | 2.4× |
| XERS Xeris Biopharma Holdings, Inc. compare | 2.2× |
| ALVO Alvotech compare | 1.6× |
| Drug Manufacturers Specialty & Generic industry median | 2.4× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on TRLV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement